Here are the 10-K annual reports from Tessera Defense and Homeland Security Inc. (HLSQ) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow HLSQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HLSQ filings page.
BiomX Inc. filed an amended annual report to add Part III information on directors, executive compensation, ownership, related-party transactions and auditor fees, and to update the cover page and officer certifications. No new financial statements are included.
The filing describes a reconstituted board and new leadership team, including CEO Michael Oster and CFO David Rokach, with three independent directors and standard audit, compensation, and nominating committees. It details 2024–2025 pay and outstanding equity awards for former executives who resigned in early 2026 and outlines non-employee director retainers and option grants.
The company discloses several related-party deals: a $3.0 million December 2025 private placement of Series Y Convertible Preferred Stock and warrants with Pyu Pyu Capital, a stock-and-note acquisition of Zorro Net Ltd. from Water IO Ltd., and a largely equity-based acquisition of DR. Frucht Systems Ltd. from Mandragola Ltd. It also notes stockholder approval of a 2026 Equity Incentive Plan for up to 1,390,000 shares, plus an annual evergreen increase.
BiomX Inc. is a clinical-stage company developing bacteriophage therapies targeting harmful bacteria in chronic conditions such as diabetic foot infections and osteomyelitis. The company has no approved products and has never generated revenue from product sales.
In December 2025 BiomX discontinued development of its cystic fibrosis candidate BX004 after adverse events and resource constraints, and later began insolvency proceedings for its Israeli subsidiary BiomX Ltd., which previously housed core operations. A court-appointed trustee now controls that subsidiary, and BiomX no longer treats it as an asset.
To address severe liquidity pressure, BiomX entered a Securities Purchase Agreement for 3,300 shares of Series Y Convertible Preferred Stock and warrants, for $3.0 million in gross proceeds. If stockholders approve the deal, the investor is expected to become the majority common stockholder and could change the company’s business, strategy and objectives. The company’s risk factors highlight substantial doubt about its ability to continue as a going concern and emphasize that its future depends heavily on securing this stockholder approval and further financing.